perflexane has been researched along with Cancer of Stomach in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ding, P; Huang, C; Li, M; Liu, H; Liu, Z; Xin, Y; Zhang, Y; Zhao, X; Zhou, H | 1 |
Liu, Z; Ran, H; Wang, Y; Wang, Z; Zhou, S | 1 |
2 other study(ies) available for perflexane and Cancer of Stomach
Article | Year |
---|---|
"PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody": Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells.
Topics: Antiviral Agents; Contrast Media; Fluorocarbons; Ganciclovir; Humans; Liposomes; Male; Receptor, ErbB-2; Simplexvirus; Stomach Neoplasms; Thymidine Kinase; Transfection; Ultrasonography | 2022 |
Targeted and pH-facilitated theranostic of orthotopic gastric cancer via phase-transformation doxorubicin-encapsulated nanoparticles enhanced by low-intensity focused ultrasound (LIFU) with reduced side effect.
Topics: Animals; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Compounding; Drug Liberation; Female; Fluorocarbons; Humans; Hydrogen-Ion Concentration; Mice, Nude; Nanoparticles; Oligopeptides; Optical Imaging; Phase Transition; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms; Theranostic Nanomedicine; Tissue Distribution; Ultrasonography | 2019 |